News and Trends 7 Oct 2022 Ziphius and UZ Ghent collaborating on manufacture of saRNA-based vaccines Ziphius Vaccines, a biopharmaceutical company developing vaccines and therapeutics based on self-amplifying RNA (saRNA), and UZ Ghent have entered a public-private collaboration for the scale up and manufacturing of prophylactic self-amplifying RNA vaccines based on GMP (good manufacturing practice) standards. The collaboration is a first in Europe where a university hospital produces GMP grade prophylactic […] October 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 Growing hub Lithuania ready to welcome biotech sector to EFIB’22 On October 26 and 27 the Lithuanian capital, Vilnius, is hosting the European Forum for Industrial Biotechnology & the Bioeconomy 2022 (EFIB’22). EFIB, one of Europe’s top biotech events, will bring together business leaders, entrepreneurs, scientists, and investors. Executive director of the Lithuanian Biotechnology Association, Agnė Vaitkevičienė, explains the importance of EFIB and the potential […] October 6, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 Catawba College and Eremid open genomics lab to offer undergrad training Catawba College and Eremid Genomic Services, LLC, a genomics contract research provider, are opening the Bill and Shari Graham Genomics Laboratory specializing in genomic sequencing at Eremid’s facilities on the North Carolina Research Campus (NCRC) in Kannapolis, North Carolina. “The Graham Genomics Lab is an example of the exceptional liberal arts education offered at Catawba […] October 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 6 Oct 2022 15 biotech companies shaking up the scene in Cambridge Cambridge has a large biotech scene that is starting to rival that of its U.S. namesake. Here are 15 biotech companies in Cambridge you should know about. The U.K. is home to several biotech hubs, including the golden triangle of London, Oxford and Cambridge, as well as Bristol and Stevenage. Cambridge is a small but […] October 6, 2022 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 Novartis Biome UK Heart Health Catalyst 2022 winners announced Novartis Pharmaceuticals UK has announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. Lifelight and PocDoc will receive support to scale their innovative digital […] October 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 New approaches beckon for small cell lung cancer treatment Small cell lung cancer (SCLC) is a particularly aggressive tumor that has so far been treated with standardized measures. However, a study led by MedUni Vienna in Austria has shown for the first time that different SCLC subtypes have specific molecular characteristics, which is why those affected respond in different ways to cancer treatment. This […] October 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 Big Idea Ventures announces cohort of 17 start-ups Big Idea Ventures has revealed its latest accelerator cohort. Seventeen early-stage startups were selected for pre-seed investment as part of Big Idea Ventures’ bi-annual new protein accelerator program. Investments were made through the firm’s three offices in New York, Paris and Singapore and the firm’s first fund – New Protein Fund I ($50 million+). “The […] October 5, 2022 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 FDA fast tracks Immutep non-small cell lung cancer candidate Immutep Limited says the United States Food and Drug Administration (FDA) has granted fast track designation to eftilagimod alpha (efti or IMP321) in combination with pembrolizumab for the treatment of first line non-small cell lung cancer (NSCLC). Efti is the company’s first-in-class soluble LAG-3 clinical stage candidate, which activates antigen presenting cells (APC) to engage […] October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 New biotech company aims to bridge gap between stem cell research and athletic injuries Andrews Medicine of Pensacola, Florida, and Celltex Therapeutics Corporation of Houston, Texas, are to form a new biotechnology company to bridge the divide between stem cell research and the current treatment of athletic injuries. The jointly owned company will operate under the name of Andrews Celltex Biologics. The new company will undertake the operation of […] October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 Transcenta monoclonal antibody gets FDA clearance Transcenta Holding Limited says its TST004 humanized monoclonal antibody targeting MASP2, has received IND clearance from the U.S. Food and Drug Administration (FDA). MASP2, mannose-binding protein-associated serine protease 2, is a key enzyme in the lectin pathway initiation of complement activation. Studies have shown that lectin pathway activation contributes to multiple human diseases such as […] October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 OncoSec slashing staff numbers to prioritize pipeline OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation. Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses. The company and remaining employees will focus clinical activities in melanoma […] October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract Intravacc has been awarded a contract with base and options that may total US$14.6 million for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). The contract has been awarded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Gonorrhea is a sexually […] October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email